HOOKIPA has dosed the first patient with HB-500 under the P-Ib study for which it received a non-dilutive milestone payment of $5M as per an agreement with Gilead. HOOKIPA will conclude the P-I study with Gilead carrying out further development
The P-Ib study aims to determine the safety, tolerability, reactogenicity & immunogenicity of repeated HB-500 doses among HIV patients on suppressive antiretroviral treatment, with recruitment underway
HB-500 consists of two genetically engineered replicating vectors from the Pichinde virus & lymphocytic choriomeningitis virus to transfer HIV antigens from highly conserved regions of HIV-1 clade B proteins
Ref: HOOKIPA | Image: HOOKIPA
Related News:- The US FDA Approves the Label Update of Gilead’s Biktarvy for Pregnant Adults with HIV
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
